Paperonium

Arthritis pain · Arthritis Rheumatol · 2019

Summary: 17% on the drug, 10% on placebo had health problems. The paper’s table: 62%, 55%.

On the drug17%The summary62%Its own table209 of 337too lowOn placebo10%The summary55%Its own table: 45 of 820%20406080
On the drug17%The summary62%Its own table209 of 337too lowOn placebo10%The summary55%Its own table45 of 820%20406080

Share of patients with any health problem, however minor, during 16 weeks of treatment

The paper says

A trial compared an arthritis-pain drug with a placebo, a look-alike with no drug. The paper’s summary says 17% on the drug and 10% on placebo had a health problem. The term it uses covers any new or worsening problem, however minor, whatever the cause.

Its own data show

The paper’s table counts 209 of 337 on the drug (four dose strengths combined) and 45 of 82 on placebo during treatment: 62% and 55%. Nothing in the paper gives 17% and 10% together: serious problems alone were 1% and 2%, and in the 20 weeks after treatment, 48% and 38%. Their source is unknown.

A placebo group shows how often problems turn up anyway: the drug’s effect is the extra on top. The summary mainly makes problems look uncommon: 1 in 6 on the drug, not 3 in 5. In proportion the drug also looks worse, 1.7 times placebo’s rate, not 1.13 times, though the extra is about 7 in 100 either way.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial · Arthritis Rheumatol (2019) · doi:10.1002/art.41012